Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Combining Oncolytic Virus Therapy with Image-Guided Radiotherapy for Tumour Treatment

FY 2016-17

Summary
Oncolytic virus (OV) therapy harnesses tumour-selective viruses to kill cancer cells while sparing normal tissues. However, OVs alone are unlikely to clear tumours completely, but can benefit other therapies due to their selectivity and systemic anti-tumour immune effects. Image-guided radiotherapy (IGRT) uses computer-modulated imaging techniques to precisely deliver ionizing radiation (IR) for tumour treatment. Although an effective treatment modality, IGRT can still miss cancer cells and furthermore, produce a therapy-induced senescent (TIS) phenotype in irradiated cancer cells which has been posited to contribute to cancer recurrences. Past studies have observed synergistic effects when OVs are combined with radiotherapy to treat cancer. Also, OVs have recently been associated with TIS cancer cell killing. Thus, combining IGRT with our unique OV may constitute a viable multimodal approach for control of tumours and recurrence. The OV used in this study is a fluorescently tagged mutant vaccinia virus with replication confined to rapidly dividing cells due to mutations in two nucleotide biosynthesis genes. This study will evaluate the therapeutic effectiveness of combining our unique OV with IGRT, compared to either treatment alone, in a preclinical model of glioma. We hypothesize that combining treatments will have better tumour control by generating additive or synergistic effects, in which IGRT will destroy the majority of the tumour mass with our OV targeting remaining cancer or IR-induced TIS cells. This research could reveal a novel method for targeting and killing TIS cells, and uncover a clinically translatable therapeutic strategy that better controls tumour growth while mitigating cancer recurrence.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367340
Name
Storozynsky Quinn
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combining Oncolytic Virus Therapy with Image-Guided Radiotherapy for Tumour Treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Therapy; Glioma; Image-Guided Radiotherapy; Oncolytic Virus Therapy; Radiation-Induced Cellular Senescence; Vaccinia Virus
Abstract
Oncolytic virus (OV) therapy harnesses tumour-selective viruses to kill cancer cells while sparing normal tissues. However, OVs alone are unlikely to clear tumours completely, but can benefit other therapies due to their selectivity and systemic anti-tumour immune effects. Image-guided radiotherapy (IGRT) uses computer-modulated imaging techniques to precisely deliver ionizing radiation (IR) for tumour treatment. Although an effective treatment modality, IGRT can still miss cancer cells and furthermore, produce a therapy-induced senescent (TIS) phenotype in irradiated cancer cells which has been posited to contribute to cancer recurrences. Past studies have observed synergistic effects when OVs are combined with radiotherapy to treat cancer. Also, OVs have recently been associated with TIS cancer cell killing. Thus, combining IGRT with our unique OV may constitute a viable multimodal approach for control of tumours and recurrence. The OV used in this study is a fluorescently tagged mutant vaccinia virus with replication confined to rapidly dividing cells due to mutations in two nucleotide biosynthesis genes. This study will evaluate the therapeutic effectiveness of combining our unique OV with IGRT, compared to either treatment alone, in a preclinical model of glioma. We hypothesize that combining treatments will have better tumour control by generating additive or synergistic effects, in which IGRT will destroy the majority of the tumour mass with our OV targeting remaining cancer or IR-induced TIS cells. This research could reveal a novel method for targeting and killing TIS cells, and uncover a clinically translatable therapeutic strategy that better controls tumour growth while mitigating cancer recurrence.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Storozynsky, Quinn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~